PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy

Inclusion Criteria: * Male or female age ≥ 18 years * Diagnosis of primary warm antibody hemolytic anemia (AIHA). * Hemoglobin \< 100g/L * Refractory to or relapsed after at least 2 prior treatment line. * ECOG performance status ≤ 2 * Willing and able to comply with the requirements for this study and written informed consent. Exclusion Criteria: * Neutrophils counts \< 0.5×10\^9/L or platelet counts \< 50 x 10\^9/L * Diagnosis of any of the following diseases: Cold agglutinin disease, cold agglutinin syndrome, mixed AIHA, paroxysmal cold hemoglobinuria (PCH). * Diagnosis of the active stage of the connective tissue or systemic autoimmune rheumatic diseases (SARDs) * History of lymphoproliferative neoplasms * Had other inherited or acquired hemolytic diseases. * Secondary AIHA caused by drugs or infection * Previously received organ or stem cell transplantation. * Had malignant tumor within 5 years before enrollment, exclusive of cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial tumor, cervical carcinoma in situ or other indolent tumors * Patients with HBV, HCV, HIV or other infections that require treatment. * Abnormal liver function: two consecutive examinations with an interval of ≥1 week suggest that ALT and AST are 2.5 times higher than the upper limit of normal values * Renal impairment: creatinine clearance \<60ml/min * Any severe and/or uncontrolled medical conditions or other conditions that could affect their particip…